Amundi Raises Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Amundi raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 95.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,323,423 shares of the company’s stock after acquiring an additional 644,665 shares during the period. Amundi’s holdings in Teva Pharmaceutical Industries were worth $22,564,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $41,000. Sound Income Strategies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% during the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares in the last quarter. MAI Capital Management increased its holdings in shares of Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares in the last quarter. CWM LLC raised its position in shares of Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after acquiring an additional 767 shares during the period. Finally, Brooklyn Investment Group boosted its stake in shares of Teva Pharmaceutical Industries by 403.4% during the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after acquiring an additional 4,014 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $29.74 on Thursday. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $29.80. The stock’s fifty day moving average is $23.03 and its two-hundred day moving average is $19.44. The firm has a market capitalization of $34.10 billion, a P/E ratio of 49.56, a price-to-earnings-growth ratio of 1.53 and a beta of 0.67.

Analysts Set New Price Targets

Several equities analysts recently weighed in on TEVA shares. Barclays began coverage on Teva Pharmaceutical Industries in a research note on Tuesday. They issued an “overweight” rating and a $35.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $30.25.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares of the company’s stock, valued at $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.